newest glp-1 medications for type 2 diabetes 2025 In the phase 3 ACHIEVE-1 trial, published in June 2025, the oral small-molecule receptor agonist orforglipron significantly reduced the glycated hemoglobin level over a period of 40 weeks in adults with GLP-1 Receptor Agonists as Treatments

Get started today with a weight loss plan thats supported, safe, and built around your body including lipotropic injections when appropriate.

With fewer regulatory hurdles than traditional tax-advantaged accounts, LSAs are simple to implement and scale across your organization

It is a tripeptide, which is a fancy way of saying it is a tiny protein made of three specific amino acids: cysteine, glycine, and glutamate

This prescription drug is designed to help patients with obesity lose weight

Alessandro Maselli, Catalent CEO (Adrien Villez for Endpoints News) November 15, 2023 11:31 AM ESTUpdated November 16, 10:31 AM Manufacturing Is the worst over

La produccin sigue estndares BPF en laboratorios con certificacin ISO